Linerixibat

Overview

Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC 50 of 42 nM human ASBT . Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Apical Sodium-Dependent Bile Acid Transporter

Product Information

• Catalog No.: HY-16643
• CAS No.: 1345982-69-5
• Molecular Formula: C28H38N2O7S
• Molecular Weight: 546.68
• Purity: 99.88%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (4.57 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source